LifeVantage Corporation
LFVNConsumer DefensiveNASDAQPackaged Foods
Scan Results
Daily timeframePart of the consumer defensive sector, LifeVantage Corporation (LFVN) is listed under Packaged Foods. At a $79.4M market cap, LifeVantage Corporation ranks as a micro-cap company within consumer defensive. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and.
Market Cap
$79.4M
Beta
0.76
P/E (TTM)
15.85
P/E (Fwd)
16.40
EPS (TTM)
$0.40
EPS (Fwd)
$0.39
ROE
14.9%
ROA
6.3%
Cash
$14.9M
Total Debt
$9.9M
Free CF
$6.0M
52W Change
-44.4%
Annual Financials
Cash vs Debt
Where LFVN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, LFVN finished 8.35% above its 150-day moving average ($5.75) and 6.31% above its 200-day moving average ($5.86). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LFVN overbought or oversold?
At the September 2, 2026 close, LFVN's RSI(14) was 41.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $14.9M in cash comfortably exceeding the $9.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $6.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 14.9%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $213.4M (2023) to $182.6M (2026), a 14% decline worth watching.
Investors considering LifeVantage Corporation should weigh the typical risks associated with LFVN's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing LFVN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.